Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Blood. 2019 Jun 13;133(24):2570-2574. doi: 10.1182/blood.2019852368. Epub 2019 Apr 9.
Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.
套细胞淋巴瘤（MCL）是一种独特的非霍奇金淋巴瘤，其特征是 cyclin D1 的过度表达。MCL 患者通常可以存活数年，但会经历多次复发。阿卡替尼是一种新型第二代口服布鲁顿酪氨酸激酶抑制剂，基于一项临床试验显示总缓解率为 81%，已被美国食品和药物管理局批准用于复发的 MCL。它为 MCL 患者提供了一种有价值的新治疗选择，目前正在进行一线治疗的测试。
